Hospital Pharmacy presents this feature to keep pharmacists abreast of new publications in the medical/pharmacy literature. Articles of interest regarding a broad scope of topics are abstracted monthly.
Get full access to this article
View all access options for this article.
References
1.
AdamsA.J.MartinS.J.StolpeS.F.“Tech-check-tech”: a review of the evidence on its safety and benefits. Am J Health Syst Pharm.2011; 68(19): 1824–1833.
2.
FowlerS.GulsethM.P.RenierC.TomscheJ.Inpatient warfarin: experience with a pharmacist-led anticoagulation management service in a tertiary care medical center. Am J Health Syst Pharm.2012; 69(1): 44–48.
3.
HasanS.S.ShamalaR.SyedI.A.Factors affecting warfarin-related knowledge and INR control of patients attending physician- and pharmacist-managed anticoagulation clinics. J Pharm Pract.2011; 24(5): 485–493.
4.
LiJ.UdyA.A.KirkpatrickC.M.Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. Int J Antimicrob Agents.2012; 39(1): 69–72.
5.
LudwigK.P.SimonsH.J.MoneM.Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ann Pharmacother.2011; 45(11): 1356–1362.
6.
PawloskiP.CusickD.AmbornL.Development of clinical pharmacy productivity metrics. Am J Health Syst Pharm.2012; 69(1): 49–54.
7.
RobertsJ.A.NorrisR.PatersonD.L.MartinJ.H.Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol.2012; 73(1): 27–36.
8.
RuderA.D.SmithD.L.MadsenM.T.KassF.H.3rdIs there a benefit to having a clinical oncology pharmacist on staff at a community oncology clinic?J Oncol Pharm Pract.2011; 17(4): 425–432.
9.
WilhelmS.M.PetrovitchE.A.Implementation of an inpatient anticoagulation teaching service: expanding the role of pharmacy students and residents in patient education. Am J Health Syst Pharm.2011; 68(21): 2086–2093.
10.
BroganS.E.WinterN.B.Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary. Pain Med.2011; 12(12): 1758–1768.
11.
RichardsJRRichardsI.N.OzeryG.DerletR.W.Droperidol analgesia for opioid-tolerant patients. J Emerg Med.2011; 41(4): 389–396.
12.
WahidiM.M.JainP.JantzM.American College of Chest Physicians consensus statement on the use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy in adult patients. Chest.2011; 140(5): 1342–1350.
13.
AveryP.J.JorgensenA.HambergA.K.; on behalf of the EU-PACT Study Group. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther.2011; 90(5): 701–706.
14.
DavisE.M.PackardK.A.KnezevichJ.T.CampbellJ.A.New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. Pharmacotherapy.2011; 31(10): 975–1016.
SalluhJ.I.F.RabelloL.S.RosolemM.M.The impact of coagulation parameters on the outcomes of patients with severe community-acquired pneumonia requiring intensive care unit admission. J Crit Care.2011; 26(5): 496–501.
17.
CiceroM.GranetoJ.Etomidate for procedural sedation in the elderly: a retrospective comparison between age groups. Am J Emerg Med.2011; 29(9): 1111–1116.
18.
LundB.C.SteinmanM.A.ChrischillesE.A.KaboliP.J.Beers criteria as a proxy for inappropriate prescribing of other medications among older adults. Ann Pharmacother.2011; 45(11): 1363–1370.
19.
MonroeT.CarterM.ParishA.A case study using the Beers list criteria to compare prescribing by family practitioners and geriatric specialists in a rural nursing home. Geriatr Nurs.2011; 32(5): 350–356.
20.
NobiliA.MarengoniA.TettamantiM.Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med.2011; 22(6): 597–602.
21.
RamaswamyR.MaioV.DiamondJ.J.Potentially inappropriate prescribing in elderly: assessing doctor knowledge, confidence and barriers. J Eval Clin Pract.2011; 17(6): 1153–1159.
22.
SinnaeveP.R.BrueckmannM.ClemensA.Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. J Intern Med.2012; 271(1): 15–24.
23.
AldeyabM.A.HarbarthS.VernazN.The impact of antibiotic use on the incidence and resistance pattern of ESBL-producing bacteria in primary and secondary healthcare settings. [published online ahead of print December 9, 2011]. Br J Clin Pharmacol.
24.
CataldoM.A.TacconelliE.GrilliE.Continuous versus intermittent infusion of vancomycin for the treatment of Grampositive infections: systematic review and meta-analysis. J Antimicrob Chemother.2012; 67(1): 17–24.
25.
Di PentimaM.C.ChanS.HossainJ.Benefits of a pediatric antimicrobial stewardship program at a children's hospital. Pediatrics.2011; 128(6): 1062–1070.
26.
DowzickyM.J.Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the Tigecycline Evaluation and Surveillance Trial (TEST) between 2004 and 2009. Clin Ther.2011; 33(12): 1964–1973.
27.
LabeauS.O.Van de VyverK.BrusselaersN.Prevention of ventilator-associated pneumonia with oral antiseptics: a systematic review and meta-analysis. Lancet Infect Dis.2011; 11(11): 845–854.
28.
NicolauD.P.CarmeliY.CrankC.W.Carbapenem stewardship: Does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents.2012; 39(1): 11–15.
29.
PalmerH.R.WestonJ.GentryL.Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm.2011; 68(22): 2170–2174.
30.
WalshT.R.TolemanM.A.The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response. J Antimicrob Chemother.2012; 67(1): 1–3.
31.
BrownJRMcCulloughP.A.SplaineM.E.; for the Northern New England Cardiovascular Disease Study Group. How do centres begin the process to prevent contrast-induced acute kidney injury: a report from a new regional collaborative. BMJ Qual Saf.2012; 21(1): 54–62.
32.
CooperW.O.HabelL.A.SoxC.M.ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med.2011; 365(20): 1896–1904.
33.
LowryE.WoodmanR.J.SoizaR.L.MangoniA.A.Associations between the anticholinergic risk scale score and physical function: potential implications for adverse outcomes in older hospitalized patients. J Am Med Dir Assoc.2011; 12(8): 565–572.
34.
PerronB.E.BohnertA.S.B.MonsellS.E.Patterns and correlates of drug-related ED visits: results from a national survey. Am J Emerg Med.2011; 29(7): 704–710.
35.
RanchonF.SallesG.SpathH.M.Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer.2011; 11(1): Article 478.
36.
SaylorM.S.SmetanaR.F.Potential for drug-drug interactions in treating cancer-related nausea and distress. J Oncol Pharm Pract.2011; 17(4): 403–408.
37.
VillanyiD.FokM.WongR.Y.M.Medication reconciliation: identifying medication discrepancies in acutely ill hospitalized older adults. Am J Geriatr Pharmacother.2011; 9(5): 339–344.
38.
AaronsonP.M.BelgadoB.S.SpillaneJ.P.KunisakiT.A.Evaluation of intramuscular fosphenytoin vs intravenous phenytoin loading in the ED. Am J Emerg Med.2011; 29(9): 983–988.
39.
ComiG.De StefanoN.FreedmanM.S.Comparison of two dosing frequencies of subcutaneous interferon beta-la in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol.2012; 11(1): 33–41.
GörenJ.L.TewksburyA.T.The use of omega-3 fatty acids in mental illness. J Pharm Pract.2011; 24(5): 452–471.
42.
SattlerA.SchaeferM.MayT.W.Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions - first clinical experience. Epilepsy Res.2011; 95(3): 207–212.
BeetzR.WestenfelderM.Antimicrobial therapy of urinary tract infections in children. Int J Antimicrob Agents.2011; 38(S1): 42–50.
45.
NairH.BrooksW.A.KatzM.Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet.2011; 378(9807): 1917–1930.
46.
RaissyH.H.BlakeK.As needed use of inhaled corticosteroids for management of mild persistent asthma in children. Pediatr Allergy Immunol Pulmonol.2011; 24(4): 231–233.
47.
Schneider-LindnerV.QuachC.HanleyJ.A.SuissaS.Antibacterial drugs and the risk of community-associated methicillin-resistant Staphylococcus aureus in children. Arch Pediatr Adolesc Med.2011; 165(12): 1107–1114.
48.
GomolinI.H.SmithC.JeitnerT.M.Donepezil dosing strategies: pharmacokinetic considerations. J Am Med Dir Assoc.2011; 12(8): 606–608.
49.
SinnollareddyM.PeakeS.L.RobertsM.S.Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. Int J Antimicrob Agents.2012; 39(1): 1–10.
50.
SpencerD.D.JacobiJ.JuenkeJ.M.Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. Pharmacotherapy.2011; 31(10): 934–941.
51.
StipE.ZhornitskyS.MoteshafiH.Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile. Clin Ther.2011; 33(12): 1853–1867.
52.
VavalleJ.P.StevensS.R.HassingerN.The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. Am Heart J.2011; 162(6): 996–1002.
53.
CaponnettoP.CibellaF.MancusoS.Effect of a nicotine-free inhalator as part of a smoking-cessation programme. Eur Respir J.2011; 38(5): 1005–1011.
54.
IpekI.O.YalcinE.U.SezerR.G.BozaykutA.The efficacy of nebulized salbutamol, hypertonic saline and salbutamol/hypertonic saline combination in moderate bronchiolitis. Pulm Pharmacol Ther.2011; 24(6): 633–637.
55.
KerwinE.M.GotfriedM.H.LawrenceD.Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther.2011; 33(12): 1974–1984.
56.
RossiA.CentanniS.CerveriI.Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med.2012; 106(1): 84–90.
57.
van NoordJ.A.SmeetsJ.J.DrenthB.M.24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther.2011; 24(6): 666–672.
58.
YuA.P.GuérinA.de LeonD.P.Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med.2011; 105(12): 1861–1871. ■
